BNTX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- BioNTech's mRNA cancer immunotherapy fails to meet its first objective in a key head and neck cancer study, but the company hopes it may still improve survivalOct 15, 2026
- BioNTech provides an update on its Phase 2/3 trial of the mRNA cancer immunotherapy candidate BNT113 in metastatic HPV16-positive head and neck cancerOct 13, 2026
- BioNTech and OncoC4 reported updated data showing gotistobart nearly doubled median overall survival versus standard chemotherapy in previously treated squamous NSCLCSep 14, 2026
- BioNTech collaboration with Bristol Myers Squibb shows encouraging Phase 2 efficacy for Pumitamig in TNBCDec 9, 2025
- First disclosure of global interim Phase 2 data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A bispecific antibody Pumitamig (BNT327/BMS986545) in extensive-stage small cell lung cancer shows encouraging antitumor activitySep 9, 2025